Skip to main content
Medical Reference · Condition Monograph

Hairy Cell Leukemia

털세포백혈병

A rare blood cancer in which abnormal lymphocytes with fine projections on their surface proliferate. It tends to progress slowly, and because effective treatments are available, the long-term outlook is relatively favorable.

History

Hairy cell leukemia (HCL) is a rare blood cancer whose identity was established relatively recently. Under the microscope, the surface of the cancer cells looks like fine hairs, and this distinctive appearance became fixed as the name of the disease. In the early days, the cause was hard to determine and treatment options were limited, so when the spleen became excessively enlarged and caused pain or anemia, surgery to remove the spleen was sometimes used as the main treatment. Later, as blood testing and bone marrow testing techniques advanced, it was established that "hairy cells" arise mainly from B lymphocytes (B cells), and criteria for distinguishing the disease from other chronic leukemias through immunophenotyping were established.

In terms of treatment, there have been several major turning points over time. With the introduction of interferon alfa (IFN-α), a disease that had once been difficult to control became "a manageable disease," and then, with the arrival of purine analog (PNA) anticancer drugs (cladribine, pentostatin), complete remission (CR) could be expected. Recently, with the addition of targeted therapies aimed at specific gene mutations, options are increasing even in cases that relapse or respond poorly to existing drugs. In initial treatment as well, a trend is taking shape of combining an anti-CD20 monoclonal antibody (rituximab) in some patients to induce deeper remission.

Causes

The "direct cause" of hairy cell leukemia has not yet been established. As with many cancers, it is understood that normal B cells turn into cancer cells through a combination of genetic changes and environmental factors rather than a single cause. Observations to date have concluded that the evidence that smoking, radiation, or exposure to common industrial chemicals clearly increases the risk is not strong. However, because some studies have observed an association with agricultural and horticultural activities, the possibility has been raised that various exposures such as soil, pesticides, and diesel exhaust may be indirectly related.

Today, the focus of research on the cause has moved closer to "which molecular switches are turned on inside the cancer cell" than to external factors. Hairy cell leukemia is characterized by excessive activation of a specific signaling pathway, and this is linked to a gene mutation. The cause is explained not as a single toxin coming from outside, but as a somatic mutation arising inside the cell that plays a more direct role in starting and sustaining the disease.

Genetic Epidemiology

Genetic epidemiology deals with "which genetic changes appear, how often, and in which groups." The most important discovery in hairy cell leukemia is the change known as the V600E mutation of the BRAF gene. This mutation is not an inherited genetic disease passed down from birth; it is understood as an acquired mutation that, in most patients, exists only in the cancer cells. In other words, rather than a "hereditary cancer" in which a family history is clearly passed on, it is closer to cancer cells proliferating as a result of a mutation that arose by chance during the life of a particular B cell.

This genetic feature changes both diagnosis and treatment direction at the same time. When a BRAF mutation is confirmed, it strongly suggests the possibility of "classic hairy cell leukemia," and conversely, in other diseases that look similar (e.g., hairy cell leukemia variant or HCL-like disorders), other mutations (e.g., MAP2K1) may be more common, which helps in differentiation. Recent studies establish the BRAF mutation as the key "driver" of classic hairy cell leukemia, and they discuss that some patients may have atypical BRAF mutations or other accompanying mutations, in which case treatment response or prognostic assessment may differ.

General Epidemiology

Hairy cell leukemia is very rare even among all leukemias. Based on Europe and the United States, its annual incidence is summarized at roughly 0.28 to 0.30 per 100,000 people, and in certain regions the prevalence is estimated to be higher. Regionally, it is known to be relatively less common in Asia, Africa, and the Middle East. In terms of sex distribution, men are clearly affected more than women, with a male-to-female ratio of about 4:1 often cited, and age at diagnosis is mostly after middle age, with the disease most often found in people in their 50s and 60s. It is summarized as almost never occurring in children.

Because this disease is often not a rapidly progressing form but a "slow-growing chronic form," diagnosis may be delayed if symptoms are not obvious, or it may be found incidentally on a blood test. With treatment, the outlook for life usually improves and long-term remission is possible, but because relapse sometimes occurs over time, long-term follow-up is important.

Pathogenesis

Put simply, the pathogenesis is the part that explains "why blood counts fall, the spleen enlarges, and infections increase." In hairy cell leukemia, abnormal B cells (hairy cells) accumulate in the bone marrow and interfere with normal blood cell production. As a result, red blood cells decrease and anemia develops; among white blood cells, neutrophils in particular decrease and the risk of infection increases; and platelets decrease so that bruising or bleeding can occur easily. A state in which several types of blood cells decrease at the same time like this is called pancytopenia.

Another axis is the spleen. When hairy cells accumulate in the spleen, the spleen enlarges (splenomegaly), and more blood cells are trapped and destroyed in the spleen or "pooled in one place," so blood test values may appear even lower. In the bone marrow, fibrosis (bone marrow fibrosis, reticulin fibrosis) may also accompany the disease, so a "dry tap" situation can occur in which the bone marrow aspirate cannot be drawn out well.

At the molecular level, the BRAF V600E mutation is explained as keeping the MAPK/ERK signaling pathway continuously switched on, inducing the cells to increase in number by "not dying and surviving for a long time." In this process, the balance of signaling substances such as inflammatory cytokines (e.g., tumor necrosis factor alpha, TNF-α) can also be disturbed. In the end, it can be understood as a structure in which an environment favorable to cancer cell survival is created in the bone marrow and spleen, and the space where normal blood cells are made shrinks.

Symptoms

Symptoms are problems the patient "feels." The most common start is fatigue and lethargy, which are closely related to anemia (a decrease in red blood cells). They may appear as shortness of breath when climbing stairs, or as tiring more easily than usual and being unable to concentrate. Frequent infections are also an important symptom: because of the decrease in white blood cells, infections such as colds or pneumonia may recur, or recovery may be slow once infected.

When the spleen enlarges, there may be a heavy feeling in the upper left abdomen, a feeling of becoming full easily, or early satiety, with reduced food intake. Bruising easily or a bleeding tendency such as nosebleeds or gum bleeding can appear when platelets decrease.

In some people, systemic symptoms such as fever, night sweats, and weight loss accompany the disease, but it is not uncommon for such "flu-like symptoms" to be less prominent than in other lymphomas. It is also known that, rarely, bone pain or bone lesions appear and can cause confusion with other diseases.

Signs

Signs are findings "observed" on examination or testing. A representative one is splenomegaly. The spleen may be felt on examination, or an enlarged spleen may be confirmed on imaging such as ultrasound or CT. On blood tests, pancytopenia is common, and monocytopenia in particular is mentioned as relatively characteristic. If hairy cells are seen on a peripheral blood smear, it is a strong clue.

On bone marrow examination, hairy cells may infiltrate the marrow with accompanying fibrosis, and because of this, bone marrow aspiration sometimes does not work well. On immunophenotyping, a combination of markers characteristic of classic hairy cell leukemia is identified, and, as adjuncts, tests for markers such as annexin A1 (ANXA1) or BRAF V600E protein help improve diagnostic accuracy.

Screening

Screening tests are tests that "broadly filter people who have no symptoms or ambiguous symptoms," but because hairy cell leukemia is very rare, there is no separate national-level screening program for the general population. Instead, screening in a practical sense begins with blood tests performed in everyday care. If white blood cells, red blood cells, and platelets are generally low on a blood test done for a health checkup or another reason, or if unexplained anemia or neutropenia recurs, further evaluation is needed.

As a next-step "check close to screening," there is the peripheral blood smear. Numbers alone have many possible causes, but if characteristic cells such as hairy cells are seen on the smear, the likelihood of the disease rises greatly. If needed, peripheral blood flow cytometry (FCM) can be performed in a relatively less invasive way to check whether there is an abnormal B-cell population. However, because definitive diagnosis usually proceeds to bone marrow testing and molecular testing, it is accurate to understand screening as merely "the stage that raises suspicion and connects to the next test."

Diagnosis

The diagnosis is confirmed by combining several clues. First, a blood test (CBC) confirms the pattern of pancytopenia, and a peripheral blood smear is used to observe the morphology of hairy cells. Next, the key elements are flow cytometry (FCM) and bone marrow examination. In the bone marrow, immunohistochemistry (IHC) is performed along with morphological observation to confirm the typical marker pattern and the degree of infiltration. Because bone marrow aspiration can fail due to fibrosis, bone marrow biopsy (trephine biopsy) becomes especially important.

In molecular testing, tests to confirm the BRAF V600E mutation play a major role. If this mutation is confirmed, the diagnostic accuracy for classic hairy cell leukemia increases, and it can also influence the choice of targeted therapy in future treatment of relapse. Imaging is not essential for every patient, but ultrasound or CT may be used when it is necessary to assess spleen size or check for complicating infections or organ enlargement.

Treatment

The broad principle of treatment is "treat when there are symptoms or when cytopenias progress meaningfully." Because the disease often progresses slowly, if blood counts are relatively stable and there are no symptoms, the patient may be managed with observation (watchful waiting). When treatment is needed, the center of traditional first-line treatment is the purine analogs (PNA) cladribine or pentostatin. These drugs produce deep remission in many patients, but because immunity can temporarily decline and the risk of infection can increase, infection management before and after treatment is very important.

Recent studies have established a trend that combining rituximab (an anti-CD20 monoclonal antibody) with a purine analog can further increase the depth or duration of remission. In cases that relapse or respond poorly to existing treatment, BRAF inhibitors (vemurafenib, dabrafenib) and, in some cases, combination with a MEK inhibitor may be considered. In addition, an immunotoxin targeting CD22 (moxetumomab pasudotox), Bruton tyrosine kinase inhibitors (BTKi), and others are also discussed in relapsed or refractory settings. Which drugs to use and in what order is decided by considering the patient's infection status, response to previous treatment, gene mutations, comorbidities, and other factors together.

Prognosis

Hairy cell leukemia is known to be a disease that "responds well to treatment," and it is summarized that with appropriate treatment, life expectancy can reach a level similar to that of the general population. However, rather than being described as cured, it is closer to a chronic disease in which long remission and the possibility of relapse coexist. Cases in which the disease-free period lasts 10 years or more after purine analog treatment have been reported, but no small number of patients relapse over time. Because such relapse is possible even several years to several decades later, long-term follow-up is needed.

Factors mentioned as determining prognosis include the degree of splenomegaly at diagnosis, the amount of hairy cells in the blood, an unusual form in which the white blood cell count is actually high (leukocytosis), and IGHV (immunoglobulin heavy chain variable region gene mutation status). Recent studies establish that VH4-34-positive cases, cases accompanied by TP53 mutations, or HCL-like disorders that are not classic hairy cell leukemia may have a less favorable prognosis.

After treatment, the risk of infection can persist for a certain period, and some studies also mention a possible increase in the risk of other cancers (second cancers). Therefore, it is realistic to view prognosis as including not only "control of the cancer itself" but also infection prevention, health checkups, and monitoring of long-term complications.

Prevention

At present, no method has been established that reliably prevents hairy cell leukemia. This is because the cause has not been clearly identified, and in most patients an acquired gene mutation appears to arise by chance. Therefore, it is difficult to make definitive recommendations such as "eating a certain food prevents it" or "following a certain lifestyle habit can stop it."

However, general cancer prevention principles are meaningful. Reducing unnecessary exposure to chemicals and, for those with frequent occupational contact with diesel exhaust, pesticides, and the like, following workplace safety rules can be helpful. In addition, in terms of "early detection," it is important to have blood tests consistently at regular health checkups and to be evaluated early if there is unexplained anemia, recurrent infections, or symptoms suggesting splenomegaly (discomfort in the upper left abdomen, early satiety, etc.).

There is also no certain way to completely prevent relapse after treatment, but infection prevention is a very practical prevention strategy. It is safe to review the vaccination plan before and after treatment (a physician's judgment is needed depending on the individual situation) and, if there are symptoms of infection, to be evaluated and treated without delay.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.